T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Post-translational modifications are induced in stressed cells which cause them to be recognised by the system. One such modification is citrullination where the positive charged arginine is modified to a neutral citrulline. We demonstrate most healthy donors show an oligoclonal CD4 response in vitro to at least one citrullinated vimentin or enolase peptide. Unlike rheumatoid arthritis patients, these T cell responses were not restricted by HLA-DRB1 shared epitope (SE) alleles, suggesting they could be presented by other MHC class II alleles. As HLA-DP is less polymorphic than HLA-DR, we investigated whether the common allele, HLA-DP4 could present citrullinated epitopes. The modification of arginine to citrulline enhanced binding of the peptides to HLA-DP4 and induced high-frequency CD4 responses in HLA-DP4 transgenic mouse models. Our previous studies have shown that tumours present citrullinated peptides restricted through HLA-DR4 which are good targets for anti-tumour immunity. In this study, we show that citrullinated vimentin and enolase peptides also induced strong anti-tumour immunity (100% survival, p < 0.0001) against established B16 tumours and against the LLC/2 lung cancer model (p = 0.034) both expressing HLA-DP4. Since most tumours do not constitutively express MHC class II molecules, models were engineered that expressed MHC class II under the control of an IFNγ inducible promoter. Immunisation with citrullinated peptides resulted in 90% survival (p < 0.001) against established B16 HHD tumour expressing IFNγ inducible DP4. These studies show that citrullinated peptides can be presented by a range of MHC class II molecules, including for the first time HLA-DP4, and are strong targets for anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Scally, S. W., Petersen, J., Law, S. C., Dudek, N. L., Nel, H. J., Loh, K. L., Wijeyewickrema, L. C., Eckle, S. B. G., van Heemst, J., Pike, R. N., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131241 · Cited by 429
Brentville, V. A., Metheringham, R. L., Gunn, B., Symonds, P., Daniels, I., Gijon, M., Cook, K., Xue, W., & Durrant, L. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1085 · Cited by 98 · cited 9×
“This response was mediated by killer CD4 T cells which secrete high amounts of IFNγ to upregulate MHC class II (MHC-II) and then directly kill the tumour cells, without the need for CD8 T cells.(9,11) We have shown that tumour recognition also depends upon autophagy.”
BackgroundMethodInfluentialSelf-citation
Cited by
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Self-citationPost-translational modifications such as citrullination are excellent targets for cancer therapy
Brentville, V. A., Vankemmelbeke, M., Metheringham, R. L., & Durrant, L. G. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101393 · Cited by 53
Self-citationMining the Immunopeptidome for Antigenic Peptides in Cancer
León-Letelier, R. A., Katayama, H., & Hanash, S. (2022) · Cancers · doi:10.3390/cancers14204968 · Cited by 16
Antigen presentation of post‐translationally modified peptides in major histocompatibility complexes
de Wit, A. S., Bianchi, F., & van den Bogaart, G. (2025) · Immunology & Cell Biology · doi:10.1111/imcb.12839 · Cited by 12
Al-Omari, A. A., Cook, K. W., Symonds, P., Skinner, A., Wright, A., Zhu, Y., Coble, V. L., Mohammed, O. J., Choudhury, R. H., Uddin, N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01029-1
Self-citation
Metadata
- Authors
- Brentville, V. A., Symonds, P., Cook, K. W., Daniels, I., Pitt, T., Gijon, M., Vaghela, P., Xue, W., Shah, S., Metheringham, R. L., & Durrant, L. G.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2019-02-20
- Volume
- 8
- Issue
- 5
- Pages
- e1576490
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2915782616
- Cited by
- 21
- References
- 3
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy. https://app.cochat.ai/papers/10.1080/2162402x.2019.1576490
- The paper
- Brentville, V. A., Symonds, P., Cook, K. W., Daniels, I., Pitt, T., Gijon, M., Vaghela, P., Xue, W., Shah, S., Metheringham, R. L., & Durrant, L. G. (2019). T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy. OncoImmunology. https://doi.org/10.1080/2162402x.2019.1576490
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.